How to Manage Estrogen on TRT

Your testosterone is being converted to estrogen right now. That process is not a flaw in your biology. It is supposed to happen, and the enzyme doing it serves a purpose that most TRT conversations completely miss.

The enzyme is called aromatase, and its job is to convert androgens into estrogens. More specifically, it converts testosterone into estradiol, which is the primary form of estrogen in men. This happens throughout your body in tissues like bone, brain, liver, and skin, but the largest site of conversion in men is adipose tissue, which is body fat. Roughly 80% of the estradiol circulating in a man's blood comes from this peripheral conversion process, with only about 20% coming directly from the testes.

So when a man starts TRT, his testosterone goes up, aromatase has more raw material to work with, and estradiol goes up with it. The labs come back elevated, the provider prescribes anastrozole, which is something called an aromatase inhibitor or AI, a drug that blocks the enzyme itself. The logic feels clean. Estrogen is high, block the thing making it.

The problem is that nobody is asking what made the conversion go up in the first place.

Aromatase does not convert testosterone at a fixed rate. The conversion is substrate-driven, which means the more testosterone available, the more conversion happens. When a man injects a large dose of testosterone cypionate once per week, testosterone peaks somewhere in the first 24 to 48 hours after the injection and then declines through the rest of the week. Estradiol trails behind by about one to two days, peaking around day three or four. That spike in testosterone creates a spike in substrate for aromatase, which creates a spike in estradiol, which is what produces the symptoms men complain about: water retention, mood swings, nipple sensitivity.

The testosterone cypionate molecule has a half-life of about 4.5 days and a mean residence time of around 8.5 days. What this means practically is that weekly injections create significant swings from peak to trough, and those swings drive both the high-estrogen symptoms at the top of the curve and the low-testosterone symptoms at the bottom. Splitting that same weekly dose into two injections reduces the peak-to-trough variance by roughly 30%. Daily injection reduces it further, mimicking the body's natural production of approximately 6 to 7 milligrams of testosterone per day.

Because aromatase conversion is substrate-driven, reducing the testosterone peak directly reduces the estradiol peak. The total weekly dose stays the same. But the spikes that create symptoms disappear, and with them, often the perceived need for an AI.

Body fat matters here in a specific way. Aromatase expression in adipose tissue is driven by a gene promoter called promoter I.4, which responds to glucocorticoids, TNF-alpha, and inflammatory cytokines. More body fat means more of those signals, which means more aromatase enzyme, which means more conversion at any given testosterone level. Research from 2015 confirmed that weight gain and inflammation directly upregulate aromatase expression in male adipose tissue, and men with obesity show measurably increased aromatase expression compared to lean men. This is also a feedback loop because higher estrogen from increased aromatase can promote further fat storage.

Alcohol directly increases aromatase activity. Insulin resistance affects both aromatase expression and something called SHBG, which stands for sex hormone binding globulin, a protein that binds testosterone in the blood and reduces how much free testosterone is available for conversion. Cortisol from chronic stress drives aromatase expression through that same promoter I.4 pathway. Poor sleep elevates cortisol and inflammatory cytokines, which loops back to the same mechanism. Genetics also play a role because individual variation in the CYP19A1 gene, which encodes aromatase, means two men on identical protocols can have meaningfully different conversion rates.

All of these are addressable. None of them require blocking the enzyme.

Here is why that distinction matters enormously. Estrogen in men is not a side effect of testosterone. It is a signal that your body depends on for bone density, cardiovascular health, cognitive function, and sexual function.

A 2013 study published in the New England Journal of Medicine tested this directly. Four hundred healthy men between 20 and 50 had their natural testosterone production suppressed, then received varying doses of testosterone with or without anastrozole to block aromatization. When aromatase was blocked and estradiol was suppressed, even with testosterone still present, sexual desire declined significantly and erectile function declined significantly. Subcutaneous fat increased two to three times in groups with suppressed estrogen. This is the study that makes the clinical logic of reflexively prescribing an AI so difficult to defend, because it isolated estrogen's independent role by keeping testosterone in the picture and removing only the estradiol.

A 2009 randomized controlled trial published in the Journal of Clinical Endocrinology and Metabolism followed 69 men over 60 who received 1 milligram of anastrozole daily for twelve months. Spine bone mineral density decreased significantly. Estradiol dropped from about 15 to 12 pg/mL, roughly a 20% reduction, and that relatively modest suppression was enough to cause measurable bone loss over the course of a year.

The clinical trap that emerges from routine AI prescribing goes like this. Large weekly injection produces estrogen symptoms. AI is prescribed. Estrogen drops too low. New symptoms appear: joint pain, erectile dysfunction, depression, increased body fat. The provider adjusts the AI dose. The patient oscillates between too high and too low, now managing two drugs to address a problem that was mostly downstream of injection frequency and modifiable lifestyle factors.

So the practical sequence is this: get a sensitive estradiol test called LC-MS/MS, which uses liquid chromatography tandem mass spectrometry and is the gold standard for measuring estradiol in men because standard immunoassay tests can cross-react with other steroids and return inaccurate readings. For most men on standard TRT doses, a target of 20 to 35 pg/mL is reasonable, and 40 to 60 may be acceptable on higher doses in men who are feeling well. Then work the drivers before touching the enzyme. Injection frequency first, because the pharmacokinetics are well understood. Body composition, alcohol, sleep, stress, and metabolic health after that.

An AI might be appropriate in a narrow subset of cases where conversion remains elevated after all other variables are addressed, but it should be the last variable adjusted, not the first.

The deeper point is this: estradiol is not the enemy of testosterone therapy. It is what testosterone therapy is partly trying to restore. Men on TRT who feel well, maintain muscle, protect their bones, and sustain sexual function are doing so in part because their estrogen is healthy, not because it is suppressed. Managing aromatase through the things that actually drive it is how you keep both sides of that system working, and blocking the enzyme without asking why it is elevated in the first place is how you trade one problem for another.

---

References

1. Finkelstein JS, Lee H, Burnett-Bowie SA, et al. 2013. Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men. New England Journal of Medicine, 36911, 1011-1022. Source
2. Burnett-Bowie SM, McKay EA, Lee H, Leder BZ. 2009. Effects of Aromatase Inhibition on Bone Mineral Density and Bone Turnover in Older Men with Low Testosterone Levels. Journal of Clinical Endocrinology and Metabolism, 9412, 4785-4792. Source
3. Pastuszak AW, et al. 2022. Pharmacokinetics of Testosterone Cypionate Delivered via Subcutaneous Autoinjector. Andrology. Source
4. Chand AL, et al. (2015). Weight gain and inflammation regulate aromatase expression in male adipose tissue. Journal of Steroid Biochemistry and Molecular Biology.
5. Bhasin S, Brito JP, Cunningham GR, et al. (2018). Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. JCEM, 103(5), 1715-1744.

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness